We’ve recently updated our valuation analysis.

Antibe Therapeutics Valuation

Is ATE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ATE?

Other financial metrics that can be useful for relative valuation.

ATE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does ATE's PB Ratio compare to its peers?

The above table shows the PB ratio for ATE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average1.3x
LABS MediPharm Labs
0.4x59.9%CA$24.0m
LOBE Lobe Sciences
1.7xn/aCA$3.8m
RAMM RAMM Pharma
0.4xn/aCA$17.7m
GLOW Glow Lifetech
2.6xn/aCA$5.1m
ATE Antibe Therapeutics
0.5x33.7%CA$24.3m

Price-To-Book vs Peers: ATE is good value based on its Price-To-Book Ratio (0.5x) compared to the peer average (1.3x).


Price to Earnings Ratio vs Industry

How does ATE's PE Ratio compare vs other companies in the CA Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a63.9%
n/an/an/a

Price-To-Book vs Industry: ATE is good value based on its Price-To-Book Ratio (0.5x) compared to the Canadian Pharmaceuticals industry average (0.9x)


Price to Book Ratio vs Fair Ratio

What is ATE's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ATE PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ATE's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of ATE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ATE's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ATE's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ATE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCA$0.47
CA$2.08
+346.2%
66.6%CA$5.00CA$0.70n/a6
Nov ’23CA$0.51
CA$2.09
+310.1%
65.8%CA$5.00CA$0.70n/a6
Oct ’23CA$0.61
CA$2.09
+242.9%
65.8%CA$5.00CA$0.70n/a6
Sep ’23CA$0.66
CA$2.09
+216.9%
65.8%CA$5.00CA$0.70n/a6
Aug ’23CA$0.60
CA$2.26
+276.4%
62.7%CA$5.00CA$0.70n/a6
Jul ’23CA$0.61
CA$1.99
+225.8%
32.3%CA$3.00CA$1.25n/a4
Jun ’23CA$0.70
CA$1.65
+135.7%
18.7%CA$2.00CA$1.25n/a3
May ’23CA$0.66
CA$1.65
+150.0%
18.7%CA$2.00CA$1.25n/a3
Apr ’23CA$0.78
CA$1.83
+134.6%
35.8%CA$3.00CA$1.20n/a5
Mar ’23CA$0.74
CA$1.83
+147.3%
35.8%CA$3.00CA$1.20n/a5
Feb ’23CA$0.70
CA$2.19
+213.1%
45.9%CA$4.00CA$1.20n/a6
Jan ’23CA$0.66
CA$2.19
+232.1%
45.9%CA$4.00CA$1.20n/a6
Dec ’22CA$0.67
CA$2.19
+227.1%
45.9%CA$4.00CA$1.20CA$0.486
Nov ’22CA$0.98
CA$2.29
+133.7%
47.0%CA$4.00CA$1.20CA$0.515
Oct ’22CA$1.20
CA$3.75
+212.5%
28.3%CA$5.00CA$2.00CA$0.616
Sep ’22CA$1.23
CA$5.42
+340.4%
80.9%CA$15.00CA$2.00CA$0.666
Aug ’22CA$3.39
CA$15.04
+343.5%
33.6%CA$24.00CA$7.00CA$0.607
Jul ’22CA$3.71
CA$15.04
+305.3%
33.6%CA$24.00CA$7.00CA$0.617
Jun ’22CA$4.22
CA$16.29
+286.1%
25.7%CA$24.00CA$10.00CA$0.706
May ’22CA$4.21
CA$16.29
+287.0%
25.7%CA$24.00CA$10.00CA$0.666
Apr ’22CA$5.09
CA$16.29
+220.1%
25.7%CA$24.00CA$10.00CA$0.786
Mar ’22CA$5.31
CA$16.29
+206.8%
25.7%CA$24.00CA$10.00CA$0.746
Feb ’22CA$3.95
CA$17.08
+332.5%
36.3%CA$30.00CA$10.00CA$0.706
Jan ’22CA$3.93
CA$18.13
+361.2%
40.7%CA$30.00CA$10.00CA$0.664
Dec ’21CA$4.08
CA$18.13
+344.2%
40.7%CA$30.00CA$10.00CA$0.674

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies